Nabriva Therapeutics PLC (STU:NTY)
€ 1.25 0.02 (1.63%) Market Cap: 2.76 Mil Enterprise Value: 1.62 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 39/100

Nabriva Therapeutics PLC at Morgan Stanley Healthcare Conference Transcript

Sep 09, 2019 / 01:55PM GMT
Release Date Price: €485 (+3.19%)
David Neil Lebowitz
Morgan Stanley, Research Division - VP

Good morning. Before we get going, let me just go through the disclosures. Please note that all important disclosures, including personal holdings disclosures, and Morgan Stanley disclosures, appear on the Morgan Stanley public website at www.morganstanley.com/researchdisclosures or at the registration desk. I'm one of the biotechnology analysts at Morgan Stanley. My name is David Lebowitz, and I am happy to have on the stage with me from Nabriva, CEO Ted Schroeder. Nabriva is a developer of first-in-class antibiotics. And certainly, the company has undergone some transition over the last year with the merger. Could you tell us a little bit about the company and its history?

Theodore R. Schroeder
Nabriva Therapeutics plc - CEO & Director

Sure. So Nabriva originally started as a research organization based in Vienna, Austria where lefamulin was discovered. So our first-in-class IV and oral antibiotics for

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot